Bruker Announces Introduction of Revolutionary d-DNP Polarizer for MRI Research and for Dynamic Nuclear Polarization Liquids NMR
Bruker has announced the successful first customer installation of its revolutionary dissolution Dynamic Nuclear Polarization (d-DNP) Polarizer at the University of California San Francisco (UCSF). The groundbreaking technology enables over 10,000x signal gains on 13C in high-field MRI and NMR systems.
The system operates at 7 Tesla and temperatures below 1.4 Kelvin, featuring Bruker's proprietary active cross-polarization technology that provides 5-10x faster polarization compared to traditional d-DNP of 13C. This advancement is particularly significant for in vivo studies of 13C-labelled metabolites, enabling real-time tracking of metabolic differences between healthy and diseased tissues in conditions like cancer.
The installation at UCSF's Hyperpolarized MRI Technology Resource Center marks a milestone in hyperpolarized MRI for preclinical research, with additional installations planned in Europe and the US. The partnership aims to validate the d-DNP technology in oncology applications.
Bruker ha annunciato la prima installazione di successo presso un cliente del suo rivoluzionario Polarizzatore di Dissoluzione con Polarizzazione Nucleare Dinamica (d-DNP) all'Università della California San Francisco (UCSF). Questa tecnologia all'avanguardia consente guadagni di segnale superiori a 10.000x su 13C nei sistemi MRI e NMR ad alto campo.
Il sistema opera a 7 Tesla e a temperature inferiori a 1.4 Kelvin, caratterizzato dalla tecnologia proprietaria di cross-polarizzazione attiva di Bruker che offre una polarizzazione da 5 a 10 volte più veloce rispetto al tradizionale d-DNP di 13C. Questo progresso è particolarmente significativo per gli studi in vivo sui metaboliti etichettati con 13C, consentendo il monitoraggio in tempo reale delle differenze metaboliche tra tessuti sani e malati in condizioni come il cancro.
L'installazione presso il Centro Risorse Tecnologiche per MRI Iperpolarizzati dell'UCSF segna una pietra miliare nella MRI iperpolarizzata per la ricerca preclinica, con ulteriori installazioni previste in Europa e negli Stati Uniti. La partnership mira a convalidare la tecnologia d-DNP nelle applicazioni oncologiche.
Bruker ha anunciado la exitosa primera instalación en un cliente de su revolucionario Polarizador de Disolución con Polarización Nuclear Dinámica (d-DNP) en la Universidad de California en San Francisco (UCSF). Esta tecnología innovadora permite ganancias de señal superiores a 10,000x en 13C en sistemas de RMN y MRI de alto campo.
El sistema opera a 7 Tesla y a temperaturas por debajo de 1.4 Kelvin, presentando la tecnología de polarización cruzada activa patentada de Bruker que proporciona una polarización de 5 a 10 veces más rápida en comparación con el d-DNP tradicional de 13C. Este avance es particularmente significativo para estudios in vivo de metabolitos etiquetados con 13C, permitiendo el seguimiento en tiempo real de las diferencias metabólicas entre tejidos sanos y enfermos en condiciones como el cáncer.
La instalación en el Centro de Recursos Tecnológicos de MRI Hiperpolarizada de UCSF marca un hito en la RMN hiperpolarizada para la investigación preclínica, con instalaciones adicionales previstas en Europa y EE. UU. La asociación tiene como objetivo validar la tecnología d-DNP en aplicaciones oncológicas.
브루커는 샌프란시스코 캘리포니아 대학교(UCSF)에서 혁신적인 용해 동적 핵 편극(d-DNP) 편극기의 첫 번째 고객 설치가 성공적으로 완료되었음을 발표했습니다. 이 획기적인 기술은 고자기장 MRI 및 NMR 시스템에서 13C의 10,000배 이상의 신호 이득을 가능하게 합니다.
이 시스템은 7 테슬라에서 작동하며 1.4 켈빈 이하의 온도에서 작동하며, 브루커의 독점적인 능동 교차 편극 기술을 특징으로 하여 전통적인 13C의 d-DNP에 비해 5-10배 더 빠른 편극을 제공합니다. 이 발전은 암과 같은 질병 상태에서 건강한 조직과 병든 조직 간의 대사 차이를 실시간으로 추적할 수 있게 해주는 13C 표지 대사체의 생체 내 연구에 특히 중요합니다.
UCSF의 하이퍼폴라리제이션 MRI 기술 자원 센터에 설치된 것은 전임상 연구를 위한 하이퍼폴라리제이션 MRI의 이정표를 의미하며, 유럽과 미국에 추가 설치가 계획되어 있습니다. 이 파트너십은 종양학 응용 분야에서 d-DNP 기술을 검증하는 것을 목표로 하고 있습니다.
Bruker a annoncé la première installation réussie chez un client de son polariseur révolutionnaire de dissolution par Polarisation Nucléaire Dynamique (d-DNP) à l'Université de Californie à San Francisco (UCSF). Cette technologie révolutionnaire permet des gains de signal supérieurs à 10 000x sur 13C dans les systèmes d'IRM et de RMN à haut champ.
Le système fonctionne à 7 Tesla et à des températures inférieures à 1,4 Kelvin, présentant la technologie de polarisation croisée active propriétaire de Bruker qui offre une polarisation de 5 à 10 fois plus rapide par rapport au d-DNP traditionnel de 13C. Cette avancée est particulièrement significative pour les études in vivo des métabolites marqués au 13C, permettant un suivi en temps réel des différences métaboliques entre les tissus sains et malades dans des conditions telles que le cancer.
L'installation au Centre de Ressources Technologiques d'IRM Hyperpolarisé de l'UCSF marque une étape importante dans l'IRM hyperpolarisée pour la recherche préclinique, avec d'autres installations prévues en Europe et aux États-Unis. Le partenariat vise à valider la technologie d-DNP dans les applications oncologiques.
Bruker hat die erfolgreiche erste Kundeninstallation seines revolutionären Polarizers für die dynamische Kernpolarisation (d-DNP) an der University of California San Francisco (UCSF) bekannt gegeben. Diese bahnbrechende Technologie ermöglicht Signalgewinne von über 10.000x bei 13C in Hochfeld-MRI- und NMR-Systemen.
Das System arbeitet bei 7 Tesla und Temperaturen unter 1,4 Kelvin und verfügt über die proprietäre aktive Kreuzpolarisationstechnologie von Bruker, die eine 5-10x schnellere Polarisation im Vergleich zur traditionellen d-DNP von 13C bietet. Dieser Fortschritt ist besonders bedeutend für in vivo-Studien von 13C-markierten Metaboliten und ermöglicht die Echtzeitverfolgung metabolischer Unterschiede zwischen gesundem und erkranktem Gewebe bei Erkrankungen wie Krebs.
Die Installation im Hyperpolarized MRI Technology Resource Center der UCSF markiert einen Meilenstein in der hyperpolarisierten MRI für die präklinische Forschung, mit weiteren Installationen, die in Europa und den USA geplant sind. Die Partnerschaft zielt darauf ab, die d-DNP-Technologie in der Onkologie zu validieren.
- First successful customer installation completed at UCSF, demonstrating market validation
- Proprietary technology enables 10,000x signal gains in MRI/NMR systems
- 5-10x faster polarization compared to traditional methods through patented cross-polarization technology
- Additional installations planned in Europe and US, indicating strong market demand
- None.
Insights
Bruker's d-DNP Polarizer represents a significant technological advancement in the specialized field of hyperpolarized MRI research. The technology's ability to achieve >10,000-fold sensitivity gains for 13C imaging addresses one of the fundamental limitations in metabolic imaging: signal strength.
What makes this technology particularly valuable is Bruker's proprietary active cross-polarization approach, which accelerates the polarization process 5-10 times faster than conventional methods. This efficiency improvement transforms what has traditionally been a time-consuming process into something more practical for research workflows.
For cancer research specifically, this technology enables real-time visualization of metabolic processes that were previously impossible to observe. By tracking 13C-labeled metabolites in vivo, researchers can better differentiate healthy from diseased tissue and monitor treatment response at a molecular level.
The successful installation at UCSF's Hyperpolarized MRI Technology Resource Center - a recognized leader in this field - provides important validation. With additional installations planned across multiple continents, this suggests growing acceptance of Bruker's approach within the research community.
While initially targeting preclinical research applications, technologies that demonstrate value in research settings often find pathways to clinical applications, though this typically involves a lengthy development cycle requiring regulatory approvals.
Bruker's introduction of the d-DNP Polarizer strengthens its position in the high-end scientific instrumentation market. This product launch aligns with the company's strategy of developing specialized, high-value tools for life science research applications.
The technology likely commands premium pricing given its specialized nature and substantial performance advantages over existing methods. While the initial target market is relatively narrow (research institutions focused on advanced metabolic imaging), the planned installations across Europe and the US indicate market acceptance and potential for near-term revenue contribution.
The proprietary aspects of this technology - particularly the patented cross-polarization approach - create competitive differentiation and potential barriers to entry, protecting Bruker's market position. This represents classic scientific instrument company strategy: develop proprietary tools that become essential for cutting-edge research.
Financially, this product likely fits within Bruker's BioSpin division, which specializes in magnetic resonance technologies. While the immediate revenue impact may be modest relative to Bruker's
The partnership with UCSF for validating oncology applications could open additional market opportunities if successful. The technology's potential to accelerate cancer research offers both commercial value and positive ESG implications, potentially broadening Bruker's investor appeal.
First successful customer installation of novel dissolution d-DNP Polarizer at UCSF
Bruker d-DNP polarizer shown (center) at UCSF, between Bruker 9.4T MRI (far left) and Fourier 80 NMR (right of polarizer). The novel d-DNP system enables >10,000x signal gains on 13C in high-field MRI and NMR systems.
Dynamic Nuclear Polarization (DNP) can enhance the sensitivity of Nuclear Magnetic Resonance (NMR) and Magnetic Resonance Imaging (MRI) by transferring polarization from electron spins to nuclear spins. Dissolution DNP (d-DNP) extends the applicability of DNP to solution-state liquids NMR and to preclinical MRI research. Polarization occurs in a separate 7 Tesla polarizer magnet at temperatures below 1.4 Kelvin, accelerated by Bruker’s proprietary active cross-polarization technology.
Subsequently, the highly polarized frozen sample is ejected, melts and dissolves, achieving sensitivity gains of over 10,000-fold in solution samples near room or body temperatures, enabling the observation of low-abundance nuclei like 13C in real-time. Hyperpolarized MRI using d-DNP is particularly beneficial for in vivo studies of 13C-labelled metabolites, enabling live tracking of chemical conversion to downstream metabolites. This highlights metabolic differences between healthy and diseased tissues for conditions ranging from cancer to cardiac health. It can be used to assess response to treatment in animal models, contributing to understanding drug efficacy and disease mechanisms.
With the novel Bruker d-DNP Polarizer, scientists can conduct previously impossible experiments in chemical or metabolic analysis in NMR and preclinical MRI. Bruker provides a faster d-DNP approach using cross polarization (CP) of 1H and 13C. This patented CP provides 5-10x faster polarization compared to traditional d-DNP of 13C. This new CP technology is a testament to Bruker's commitment to pushing boundaries and empowering scientists to conduct groundbreaking research.
Professor Renuka Sriram, who leads the preclinical Hyperpolarized Magnetic Resonance Imaging group at UCSF, highlighted the significance: "The Bruker d-DNP Polarizer is a pivotal new tool for our research team. This will enable us to explore metabolic pathways that are only accessible with dissolution DNP. Bruker’s much faster CP-based d-DNP technology and automated d-DNP system further enhance our ability to develop diagnostics for cancers and other metabolic conditions."
Professor Dan Vigneron, Director of the Hyperpolarized Imaging Center at UCSF, elaborated: "With this advanced d-DNP system, we can accelerate our preclinical research efforts and contribute to the development of more effective diagnostic tools. Our collaboration with Bruker is instrumental in pushing the boundaries of what is possible in hyperpolarized MRI."
"At Bruker, we are committed to driving innovation in the field of hyperpolarization," stated Dr. James Kempf, Senior Manager DNP & Hyperpolarization at Bruker BioSpin. "The installation of our d-DNP Polarizer at UCSF exemplifies our dedication to advancing scientific research, and it also highlights our partnerships with leading institutions to develop cutting-edge technologies to transform healthcare."
As the research community begins to harness the capabilities of the Bruker d-DNP Polarizer, the potential for pioneering discoveries in metabolic imaging and disease diagnostics is immense. The collaboration between Bruker and UCSF is set to pave the way for future advancements in hyperpolarized MRI. Additional d-DNP customer installations are already planned in
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402925205/en/
Investor Contact:
Joe Kostka
Director - Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Media Contact:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 373-3531
E: pr@bruker.com
Source: Bruker Corporation
FAQ
What are the key benefits of Bruker's new d-DNP Polarizer for MRI research?
How does BRKR's d-DNP technology improve cancer research?
Where has BRKR installed its first d-DNP Polarizer system?
What are the expansion plans for BRKR's d-DNP Polarizer technology?
